詳細検索はこちら

竹内 正義 タケウチ マサヨシ

所属部署名先端医療研究領域
職名教授
 
 

研究者基本情報

研究

    研究の概要:
    生活習慣病の発症・進展における新規ターゲットとしてのToxic AGEs (TAGE)の関与とその阻止

専門分野

  • 医歯薬学
    健康と食生活
  • 代謝学
  • 生物系薬学

学歴

  • 北陸大学 大学院 薬学研究科博士前期課程
  • 北陸大学 薬学部 薬学科

学位

  • 薬学博士

所属学協会

  • 1996年日本糖尿病学会 会員
  • 2010年日本抗加齢医学会 会員
  • 2008年- 2015年日本未病システム学会 評議員
  • 1980年日本薬学会 会員
  • 1997年日本メイラード学会 会員
  • 2003年日本アルコール医学生物学研究会 会員

経歴

  • 2004年11月- 2011年03月北陸大学薬学部 教授
  • 2011年04月金沢医科大学総合医学研究所 教授

研究活動情報

研究分野

  • 複合領域 / 健康・スポーツ科学
    食生活
    研究課題: 現代の飲食物が関与する細胞内毒性終末糖化産物の生成/蓄積と各種細胞障害機序の解明

論文

  • 生活習慣病の発症・進展における新規バイオマーカーToxic AGEs (TAGE)高田尊信, 逆井(坂井)亜紀子, 竹内正義日本未病システム学会雑誌24:27-332018年08月
  • NAFLDとALDの発症・進展におけるToxic AGEs(TAGE)病因説逆井(坂井)亜紀子, 瀧野純一, 福村敦, 高田尊信, 堤幹宏, 竹内正義日本未病システム学会雑誌24:19-252018年03月
  • Role of Glyceraldehyde-Derived AGEs and Mitochondria in Superoxide Production in Femoral Artery of OLETF Rat and Effects of Pravastatin(Hori, Eisei);Kikuchi, Chigusa;Nagami, Chie;Kajikuri, Junko;Itoh, Takeo;Takeuchi, Masayoshi;Matsunaga, TamihideBIOLOGICAL & PHARMACEUTICAL BULLETIN40:1903-19082017年11月
  • Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell deathAkiko Sakasai-Sakai,Takanobu Takata,Jun-ichi Takino,Masayoshi TakeuchiScientific Reports7:142822017年10月
  • Glyceraldehyde-Derived Advanced Glycation End Products Accumulate Faster Than N-epsilon-(Carboxymethyl) Lysine(Yokota, Mami);Sekita, Marie;Okano, Yuri;Masaki, Hitoshi;Takeuchi, Masayoshi;Tokudome, YoshihiroANNALS OF DERMATOLOGY29:508-5112017年08月
  • Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotionTakanobu Takata, Tadashi Ueda, Akiko Sakasai-Sakai, Masayoshi TakeuchiWorld Journal of Gastroenterology23:4910-49192017年07月
  • Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALDMasayoshi Takeuchi, Jun-ichi Takino, Akiko Sakasai-Sakai, Takanobu Takata, Mikihiro TsutsumiNutrients9:6342017年06月
  • High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia.(Sannohe Takahiro);Ohnuma Tohru;Takeuchi Masayoshi;Tani Eriko;Miki Yasue;Takeda Mayu;Katsuta Narimasa;Takebayashi Yuto;Nakamura Toru;Nishimon Shohei;Kimoto Ayako;Higashiyama Ryoko;Shibata Nobuto;Gohda Tomohito;Suzuki Yusuke;Yamagishi Sho-Ichi;Tomino Yasuhiko;Arai HeiiProgress in Neuro-Psychopharmacology & Biological Psychiatry76:42-482017年06月
  • Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans.N.Tomosugi, S.Yamamoto, M.Takeuchi, H.Yonekura, Y.Ishigaki, N.Numata, S.Katsuda, Y.SakaiJournal of atherosclerosis and thrombosis24:530-5382017年05月
  • Effect of Collagen Tripeptide on Atherosclerosis in Healthy HumansNaohisa Tomosugi, Shoko Yamamoto, Masayoshi Takeuchi, Hideto Yonekura, Yasuhito Ishigaki, Noriaki Numata, Shogo Katsuda, Yasuo SakaiJournal of Atherosclerosis and Thrombosis24:530-5382017年05月
  • Gene Expression Changes Associated with the Loss of Heterogeneous Nuclear Ribonucleoprotein M Function(Jun-ichi Takino), Kentaro Nagamine, Mikoto Suzuki, Akiko Sakasai-Sakai, Masayoshi Takeuchi, Takamitsu HoriAmerican Journal of Molecular Biology7:87-982017年04月
  • Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects(Tahara, Atsuko);Tahara, Nobuhiro;Yamagishi, Sho-ichi;Honda, Akihiro;Igata, Sachiyo;Nitta, Yoshikazu;Bekki, Munehisa;Nakamura, Tomohisa;Sugiyama, Yoichi;Sun, Jiahui;Takeuchi, Masayoshi;Shimizu, Makiko;Yamazaki, Hiroshi;Fukami, Kei;Fukumoto, YoshihiroINTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION68:1013-10202017年04月
  • Diurnal glycemic fluctuation is associated with severity of coronary artery disease in prediabetic patients: Possible role of nitrotyrosine and glyceraldehyde-derived advanced glycation end products.M.Watanabe, Y.Kawai, M.Kitayama, H.Akao, A.Motoyama, M.Wakasa , R.Saito, H.Aoki, K.Fujibayashi, T.Tsuchiya, H.Nakanishi, K.Saito, M.Takeuchi, K.KajinamiJournal of Cardiology69:625-6312017年04月
  • 非アルコール性脂肪性肝疾患(NAFLD)の発症・進展におけるToxic AGEs(TAGE)の関与竹内正義, 逆井亜紀子, 高田尊信, 上田忠司, 瀧野純一日本未病システム学会雑誌23:20-302017年
  • Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).(M.Shimomura), J.Oyama, M.Takeuchi, Y.Shibata, Y.Yamamoto, T.Kawasaki, H.Komoda, K.Kodama, M.Sakuma, S.Toyoda, Y.Inoue, Mine Daigo, M.Natsuaki, A.Komatsu, Y.Hikichi, S.Yamagishi, T.Inoue , K.NodeHeart and vessels31:1583-15892016年
  • Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related DiseasesM.TakeuchiDiagnostics6:1-222016年
  • 糖化制御と未病~AGEs-RAGE系からみた未病対策~未病におけるToxic ages (tage) の関与とその阻止 (TAGE)竹内正義循環器病・介護予防に向けた未病ガイドライン:68-782016年
  • Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma(J.Takino), K.Nagamine, T.Hori, A.Sakasai-Sakai, M.TakeuchiWorld Journal of Hepatology7:2459-24692015年08月
  • Toxic AGEs (TAGE) theory in the pathogenesis of NAFLD and ALDM.Takeuchi, A.Sakasai-Sakai, J.Takino, T.Takata, T.Ueda, M.TsutsumiInternational Journal of Diabetes and Clinical Researsh2:1-52015年07月
  • 脂質異常症患者に対する脂質低下療法がGlycer-AGEsにもたらす影響廣正修一, 竹内正義診療と新薬52:513-5192015年05月
  • 不妊治療バイオマーカーとしてのToxic AGEs(TAGE)の有用性逆井(坂井)亜紀子, 神野正雄, 竹内正義日本未病システム学会雑誌21:932015年03月
  • 生活習慣病の発症・進展におけるToxic AGEs (TAGE) の関与 -新たな予防戦略- ~食事性AGEsおよび糖毒性の真実~竹内正義, 瀧野純一, 逆井(坂井)亜紀子, 高田尊信, 上田忠司金沢医科大学雑誌40:95-1032015年
  • The association between glyceraldehyde-derived advanced glycation end-products and colorectal cancer risk(S.Y.Kong), M.Takeuchi, H.Hyogo, G.McKeown-Eyssen, S.Yamagishi, K.Chayama, P.J.O'Brien, P.Ferrari, K.Overvad, A.Olsen, A.Tjonneland, M.Boutron-Ruault, N.Bastide, F.Carbonnel, T.Kuehn, R.Kaaks, H.Boeing, K.Aleksandrova, A.Trichopoulou, P.Lagiou, E.Vasilopoulou, G.Masala, V.Pala, M.D.Magistris, R.Tumino, A.Naccarati, H.B.Bueno-De-Mesquita, P.H.Peeters, E.Weiderpass, J.R.Quiros, P.Jakszyn, M.Sanchez, M.Dorronsoro, D.Gavrila, E.Ardanaz, M.Rutegard, H.Nystroem, N.Wareham, K.Khaw, K.Bradbury, I.Romieu, H.Freisling, F.Stavropoulou, M.J.Gunter, A.J.Cross, E.Riboli, M.Jenab, W.R.BruceCancer Epidemiology Biomarkers & Prevention24:1855-18632015年
  • Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.M.Takeuchi, A.Sakasai-Sakai, T.Takata, T.Ueda, J.Takino, M.Tsutsumi, H.Hyogo, S.YamagishiMedical Hypotheses84:490-4932015年
  • Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function(M.Kajikawa), A.Nakashima, N.Fujimura, T.Maruhashi, Y.Iwamoto, A.Iwamoto, T.Matsumoto, N.Oda, T.Hidaka, Y.Kihara, K.Chayama, C.Goto, Y.Aibara, K.Noma, M.Takeuchi, T.Matsui, S.Yamagishi, Y.HigashiDiabetes Care38:119-1252015年
  • Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients(K.Fukami), S.Yamagishi, K.Sakai, Y.Kaida, M.Yokoro, S.Ueda, Y.Wada, M.Takeuchi, M.Shimizu, H.Yamazaki, S.OkudaJournal of Cardiovascular Pharmacology65:289-2952015年
  • In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM(J.Takino), K.Nagamine, M.Takeuchi, T.HoriWorld Journal of Gastroenterology21:1784-17932015年
  • Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells(Y.Koriyama), A.Furukawa, M.Muramatsu, J.Takino, M.TakeuchiScientific Reports5:1-72015年
  • Elevation of serum levels of advanced glycation end products in patients with non-B or non-C hepatocellular carcinoma(H.Kan), S.Yamagishi, A.Ojima, K.Fukami, S.Ueda, M.Takeuchi, H.Hyogo, H.Akita, K.ChayamaJournal of Clinical Laboratory Analysis29:480-4842015年
  • Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT(N.Tahara), S.Yamagishi, N.Kodama, A.Tahara, A.Honda, Y.Nitta, S.Igata, T.Matsui, M.Takeuchi, H.Kaida, S.Kurata, T.Abe, Y.FukumotoJournal of Clinical Endocrinology & Metabolism100:E739-E7472015年
  • Assessment of total sugar and glucose concentrations in commonly consumed beverages in JapanM.Takeuchi, J.Takino, H.Shirai, M.Kawakami, S.Furuno, Y.KobayashiNutrition and Food Technology:Open Access1:1-92015年
  • Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in JapanM.Takeuchi, J.Takino, S.Furuno, H.Shirai, M.Kawakami, M.Muramatsu, Y.Kobayashi, S.YamagishiPLoS One10:e0118652-e01186522015年
  • Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia(M.Takeda), T.Ohnuma, M.Takeuchi, N.Katsuta, H.Maeshima, Y.Takebayashi, M.Higa, T.Nakamura, S.Nishimon, T.Sannohe, Y.Hotta, R.Hanzawa, R.Higashiyama, N.Shibata, T.Gohda, Y.Suzuki, S.Yamagishi, Y.Tomino, H.AraiNeuroscience Letters593:51-552015年
  • Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.M.Takeuchi, J.Takino, A.Sakasai-Sakai, T.Takata, T.Ueda, M.Tsutsumi, H.Hyogo, S.YamagishiWorld journal of hepatology [electronic resource]6:880-8932014年12月
  • Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation.(Z.Dong), D.Iwata, N.Kitaichi, M.Takeuchi, M.Sato, N.Endo, K.Iwabuchi, R.Ando, J.Fukuhara, S.Kinoshita, A.Lennikov, M.Kitamura, K.Mizuuchi, A.Kanda, K.Noda, K.Namba, S.Yamagishi, S.Ohno, S.IshidaJournal of leukocyte biology96:1077-10852014年12月
  • Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.(K.Yanagisawa), J.Ashihara, S.Obata, N.Wada, M.Takeuchi, Y.Nishino, S.Maeda, Y.Ishibashi, S.YamagishiDiabetes/metabolism research and reviews30:693-7002014年11月
  • Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products.(S.Maeda), T.Matsui, A.Ojima, M.Takeuchi, S.YamagishiNutrition research.34:807-8132014年09月
  • Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.(S.Nakashima), T.Matsui, M.Takeuchi, S.YamagishiHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.46:717-7212014年09月
  • Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris.(T.Nozue), S.Yamagishi, M.Takeuchi, T.Hirano, S.Yamamoto, S.Tohyama, K.Fukui, S.Umezawa, Y.Onishi, T.Kunishima, K.Hibi, M.Terashima, I.MichishitaIJC metabolic & endocrine.4:47-522014年07月
  • DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice.(A.Ojima), T.Matsui, S.Maeda, M.Takeuchi, H.Inoue, Y.Higashimoto, S.YamagishiLaboratory investigation; a journal of technical methods and pathology.94:422-4292014年04月
  • Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic β-cells.(H.Hachiya), Y.Miura, K.Inoue, K.H.Park, M.Takeuchi, K.KubotaJournal of hepato-biliary-pancreatic sciences.21:134-1412014年02月
  • Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.(I.Nakamura), J.Oyama, H.Komoda, A.Shiraki, Y.Sakamoto, I.Taguchi, A.Hiwatashi, A.Komatsu, M.Takeuchi, S.Yamagishi, T.Inoue, K.NodeCardiovascular diabetology [electronic resource]13:15;1-82014年01月
  • DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude miceOjima, Ayako;Matsui, Takanori;Maeda, Sayaka;Takeuchi, Masayoshi;Inoue, Hiroyoshi;Higashimoto, Yuichiro;Yamagishi, Sho-ichiLABORATORY INVESTIGATION94:422-4292014年
  • Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formationDong, Zhenyu;Iwata, Daiju;Kitaichi, Nobuyoshi;Takeuchi, Masayoshi;Sato, Masashi;Endo, Noriko;Iwabuchi, Kazuya;Ando, Ryo;Fukuhara, Junichi;Kinoshita, Satoshi;Lennikov, Anton;Kitamura, Mizuki;Mizuuchi, Kazuomi;Kanda, Atsuhiro;Noda, Kousuke;Namba, Kenichi;Yamagishi, Sho-Ichi;Ohno, Shigeaki;Ishida, SusumuJOURNAL OF LEUKOCYTE BIOLOGY96:1077-10852014年
  • Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic -cellsHachiya, Hiroyuki;Miura, Yoshikazu;Inoue, Ken-ichi;Park, Kyung Hwa;Takeuchi, Masayoshi;Kubota, KeiichiJOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES21:134-1412014年
  • Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product(AGE) - receptor for AGE(RAGE) axis, and albuminuria in Japanese type 2 diabetes.(K.Sakata), M.Hayakawa, Y.Yano, N.Tamaki, N.Yokota, T.Eto, R.Watanabe, N.Hirayama, T.Matsuo, K.Kuroki, S.Sagara, O.Mishima, M.Koga, N.Nagata, Y.Nishino, K.Kitamura, K.Kario, M.Takeuchi, S.YamagishiDiabetes/metabolism research and reviews29:624-6302013年11月
  • Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.(Y.Higashimoto), T.Matsui, Y.Nishino, J.Taira, H.Inoue, M.Takeuchi, S.YamagishiMicrovascular research90:64-702013年11月
  • Presence of glyceraldehyde-derived advanced glycation end-products in the liver of insulin-resistant mice(Y.Ebata), J.Takino, H.Tsuchiya, T.Sakabe, Y.Ikeda, S.Hama, K.Kogure, M.Takeuchi, G.ShiotaInternational journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.83:137-1412013年09月
  • Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction.(R.Ando), S.Ueda, S.Yamagishi, H.Miyazaki, Y.Kaida, K.Kaifu, M.Yokoro, Y.Nakayama, N.Obara, K.Fukami, M.Takeuchi, S.OkudaDiabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease.10:436-4412013年09月
  • DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathyHigashimoto, Yuichiro;Kaida, Yusuke;Matsui, Takanori;Fukami, Kei;Okuda, Seiya;Yamagishi, Sho-ichi;Takeuchi, Masayoshi;Inoue, HiroyoshiJOURNAL OF PHARMACOLOGICAL SCIENCES124:225P-225P2013年09月
  • DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy(Y.Kaida), K.Fukami, T.Matsui, Y.Higashimoto, Y.Nishino, N.Obara, Y.Nakayama, R.Ando, M.Toyonaga, S.Ueda, M.Takeuchi, H.Inoue, S.Okuda, S.YamagishiDiabetes.62:3241-32502013年09月
  • Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF(N.Tahara), S.Yamagishi, A.Tahara, M.Takeuchi, T.ImaizumiInternational journal of cardiology167:3072-30742013年09月
  • Telmisartan inhibits AGE-induced podocyte damage and detachment.(K.Fukami), S.Yamagishi, K.Kaifu, T.Matsui, Y.Kaida, S.Ueda, M.Takaeuchi, K.Asanuma, S.OkudaMicrovascular research88:79-832013年07月
  • Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.(S.Maeda), T.Matsui, M.Takeuchi, S.YamagishiDiabetes/metabolism research and reviews29:406-4122013年07月
  • Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease.N.Hayashi, J.George, M.Takeuchi, A.Fukumura, N.Toshikuni, T.Arisawa, M.TsutsumiPloS one8:e70034;1-142013年07月
  • 透析患者における血清終末糖化産物(AGEs)濃度-セベラマー塩酸塩少量投与の効果-(村本弘昭), 武藤寿生, 竹内正義日本透析医学会雑誌46:467-4732013年05月
  • 糖化制御と未病 AGEs-RAGE系からみた未病対策 未病におけるToxic AGEs(TAGE)の関与とその阻止竹内正義日本未病システム学会雑誌19:71-782013年05月
  • Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients.(Y.Yano), M.Hayakawa, K.Kuroki, H.Ueno, S.Yamagishi, M.Takeuchi, T.Eto, N.Nagata, M.Nakazato, K.Shimada, K.KarioAtherosclerosis.227:135-1392013年03月
  • 血管障害バイオマーカーとしてのtoxic AGEs (TAGE)竹内正義医学のあゆみ244:685-6902013年02月
  • 糖化を防いで生活習慣病予防!~TAGE-RAGE系からみた新たな治療戦略~竹内正義O.li.v.e.―骨代謝と生活習慣病の連関―3:51-532013年02月
  • Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: The JAPAN-ACS sub-study.(Y.Fukushima), H.Daida, T.Morimoto, T.Kasai, K.Miyauchi, S.Yamagishi, M.Takeuchi, T.Hiro, T.Kimura, Y.Nakagawa, M.Yamagishi, Y.Ozaki, M.MatsuzakiCardiovascular diabetology [electronic resource]0.5034722222013年01月
  • PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation.(Y.Ishibashi), T.Matsui, K.Ohta, R.Tanoue, M.Takeuchi, K.Asanuma, K.Fukami, S.Okuda, K.Nakamura, S.YamagishiMicrovascular research85:54-582013年01月
  • Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.(A.Ojima), Y.Ishibashi, T.Matsui, S.Maeda, Y.Nishino, M.Takeuchi, K.Fukami, S.YamagishiThe American journal of pathology.182:132-1412013年01月
  • 生活習慣病の発症・進展におけるToxic AGEs (TAGE)-RAGE系の関与:-新たな治療戦略-竹内正義金沢医科大学雑誌37: 141-1612012年12月
  • Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.(N.Tahara), S.Yamagishi, M.Takeuchi, A.Tahara, K.Kaifu, S.Ueda, S.Okuda, T.ImaizumiClinical biochemistry46:300-3032012年12月
  • Positive association between serum level of glyceraldehyde-derived advanced glycation end products (AGEs) and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET).(N.Tahara), S.Yamagishi, M.Takeuchi, A.Honda, A.Tahara, Y.Nitta, N.Kodama, M.Mizoguchi, H.Kaida, M.Ishibashi, N.Hayabuchi, T.Matshui, T.ImaizumiDiabetes Care.35:2618-26252012年12月
  • Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase.(Y.Ishibashi), T.Matsui, M.Takeuchi, S.YamagishiHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.45:387-3902012年12月
  • Serum levels of pigment epithelium-derived factor, a novel marker of insulin resistance, are independently associated with fasting apolipoprotein B48 levels in humans(N.Tahara), S.Yamagishi, A.Tahara, M.Takeuchi, T.ImaizumiClinical biochemistry45:1404-14082012年11月
  • Metoformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.(Y.Ishibashi), T.Matsui, M.Takeuchi, S.YamagishiHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.44:891-8952012年11月
  • Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.(Y.Ishibashi), S.Yamagishi, T.Matsui, K.Ohta, R.Tanoue, M.Takeuchi, S.Ueda, K.Nakamura, S.OkudaMetabolism: clinical and experimental61:1067-10722012年08月
  • Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation.(N.Tahara), S.Yamagishi, A.Tahara, M.Ishibashi, N.Hayabuchi, M.Takeuchi, T.ImaizumiInternational journal of cardiology158:461-4622012年07月
  • Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its anti-oxidative properties.(A.Ojima), T.Matsui, S.Maeda, M.Takeuchi, S.YamagishiHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.44:501-5052012年06月
  • Toxic advanced glycation end-products: TAGEの多様な疾患への関与竹内正義日本薬理学雑誌139:193-1972012年05月
  • Glycer-AGEs-RAGE signaling enhances the angiogenic potential of HCC by upregulating VEGF expression.(J.Takino), S.Yamagishi, M.TakeuchiWorld journal of gastroenterology : WJG.18:1781-17882012年04月
  • Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.(Y.Ishibashi), T.Matsui, M.Takeuchi, S.YamagishiPharmacological research : the official journal of the Italian Pharmacological Society.65:297-3022012年03月
  • AGEsと肝疾患竹内正義Anti-Aging Medicine8:55-612012年02月
  • Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)- RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase- mediated oxidative stress generation(S.Maeda), T.Matsui, M.Takeuchi, S.YamagishiInternational journal of cardiology152:408-4102011年11月
  • Sitagliptin augments suppressive effects of GLP-1 on advanced glycation end product (AGE)-receptor axis in endothelial cells(Y.Ishibashi), T.Matsui, M.Takeuchi, S.YamagishiHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.43:731-7342011年09月
  • Glucagon-like peptide-1 suppresses advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing AGE receptor level(Y.Ishibashi), Y.Nishino, T.Matsui, M.Takeuchi, S.YamagishiMetabolism: clinical and experimental60:1271-12772011年09月
  • Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1(Y.Ishibashi), T.Matsui, M.Takeuchi, S.YamagishiHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.43: 619-6242011年08月
  • Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells.(T.Suga), T.Iso, T.Shimizu, T.Tanaka, S.Yamagishi, M.Takeuchi, T.Imaizumi, M.KurabayashiJournal of atherosclerosis and thrombosis.18:670-6832011年08月
  • 生活習慣病におけるToxic AGEs (TAGE)-RAGE系の関与とその阻止竹内正義日本未病システム学会雑誌17:73-792011年07月
  • Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP.(Y.shibashi), T.Matsui, M.Takeuchi, S.YamagishiClinical and experimental medicine11:131-1352011年06月
  • Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease(T.Nakamura), E.Sato, N.Fujuwara, Y.Kawagoe, H.Koide, Y.Ueda, M.Takeuchi, S.YamagishiClinical cardiology.34:372-3772011年06月
  • NASHの発症・進展におけるtoxic AGEs (TAGE)-RAGE系の関与竹内正義, 瀧野純一, 兵庫秀幸, 山岸昌一アルコールと医学生物学30:100-1062011年04月
  • Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis(T.Matsui), Y.Nishino, M.Takeuchi, S.YamagishiPharmacological research : the official journal of the Italian Pharmacological Society.63:383-3882011年03月
  • Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.(Maeda S), Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi SPharmacological research : the official journal of the Italian Pharmacological Society.63: 241-2482011年03月
  • Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells(T.Matsui), Y.Nishino, S.Maeda, M.Takeuchi, S.YamagishiMicrovascular research81:269-2732011年03月
  • Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in Zucker fatty rats by suppressing advanced glycation end product receptor axis.(Miura K), Kitahara Y, Kajioka T, Takeuchi M, Yamagishi SHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.43: 226-2282011年03月
  • Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology.(Jinno M), Takeuchi M, Watanabe A, Teruya K, Hirohama J, Eguchi N, Miyazaki AHuman reproduction (Oxford, England)26: 604-6102011年03月
  • Co-treatement with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs)-elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.(Maeda S), Matsui T, Takeuchi M, Yamagishi SInternational journal of cardiology146: 264-2662011年02月
  • Involvement of aldosterone-mineralcorticoid receptor system in advanced glycation end product (AGE)- elicited plasminogen activator inhibitor-1 (PAI-1) expression in diabetes.(Matsui T), Takeuchi M, Yamagishi SInternational journal of cardiology145: 566-5672010年12月
  • MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.(Sakuraoka Y), Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Osawa T, Adaci M, Takino J, Takeuchi M, Kubota KWorld journal of gastroenterology : WJG.16: 5334-53412010年11月
  • Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: A novel therapeutic strategy.Takeuchi M, Takino J, Yamagishi SCurrent drug targets11: 1468-14822010年11月
  • Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)- induced platelet CD40 ligand overexpression in rats.(Yamagishi S), Matsui T, Ueda S, Takeuchi MInternational journal of cardiology144: 283-2852010年10月
  • Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin(Unoki-Kubota H), Yamagishi S, Takeuchi M, Bujo H, Saito YProtein and peptide letters17: 1177-11812010年09月
  • Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.(Ide Y), Matsui T, Ishibashi Y, Takeuchi M, Yamagishi SMicrovascular research80: 227-2322010年09月
  • Atorvastain reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).(Nakamura T), Sato E, Fujiwara N, Nawagoe Y, Takeuchi M, Maeda S, Yamagishi SOxidative medicine and cellular longevity3: 304-3072010年09月
  • Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-(Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda SBiochemical and biophysical research communications398: 326-3302010年07月
  • Insulin resistence is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men.(Tahara N), Imaizumi T, Takeuchi M, Yamagishi SOxidative medicine and cellular longevity3: 262-2652010年07月
  • Immunological detection of fructose-derived advanced glycation end-products.Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, Yamagishi SLaboratory investigation; a journal of technical methods and pathology.90: 1117-11272010年07月
  • Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.(Kimura Y), Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama KJournal of gastroenterology.45: 750-7572010年07月
  • Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy.Takeuchi M, Takino J, Yamagishi SJournal of ophthalmology2010: 1703932010年06月
  • Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products.(Takino J), Yamagishi S, Takeuchi MJournal of oncology.2010: 7398522010年06月
  • An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes.(Tsunosue M), Mashiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M, Tanaka S, Hoshiko M, Yoshiyama Y, Takeuchi M, Ueda S, Yamagishi SClinical and experimental medicine10: 139-1412010年06月
  • Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced(Matsui T), Takeuchi M, Yamagishi SBiochemical and biophysical research communications396: 566-5702010年05月
  • Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population.(Yamagishi S), Matsui T, Adachi H, Takeuchi MPharmacological research : the official journal of the Italian Pharmacological Society.61: 103-1072010年02月
  • The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.(Takino J), Kobayashi Y, Takeuchi MJournal of gastroenterology.45: 646-6552010年01月
  • Neuropathy induced by exogenously administered advanced glycation end-products in rats.(Nishizawa Y), Wada R, Baba M, Takeuchi M, Hanyu-Ishibashi C, Yagihashi SJournal of diabetes investigation1: 40-492010年01月
  • Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.(Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda SPharmacological research : the official journal of the Italian Pharmacological Society.61: 34-392010年01月
  • Glucagon-like peptide-1 (GLP-1) inihibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression.(Ishibashi Y), Matsui T, Takeuchi M, Yamagishi SBiochemical and biophysical research communications391: 1405-14082010年01月
  • Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock(Nakamura T), Sato E, Fujiwara N, Kawagoe W, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi SPharmacological research : the official journal of the Italian Pharmacological Society.60: 515-5182009年12月
  • Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients(Nakamura T), Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada Y, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi SMetabolism: clinical and experimental58: 1624-16282009年11月
  • Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects(Yamagishi S), Adachi H, Matsui T, Nakamura K, Takeuchi M, Enomoto M, Fukami A, Otsuka M, Kumagae S, Nanjo Y, ueda S, Imaizumi TClinical cardiology.32: E12-E152009年09月
  • Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease.Takeuchi M, Yamagishi SJournal of Alzheimer's disease : JAD16: 845-8582009年08月
  • Up-regulation in receptor for advanced glycation end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro(Yoshida T), Park JS, Yokosuka K, Jinbo K, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata KSpine34: 1544-15482009年07月
  • Nifedipine, a calcium channel blocker, inhibits advanced glycation end products (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammma activation(Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda SBiochemical and biophysical research communications385: 269-2722009年07月
  • Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs)(Yamagishi S), Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue HDiabetes/metabolism research and reviews25: 266-2712009年03月
  • Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients(Nakamura K), Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi SMetabolism: clinical and experimental58: 421-4252009年03月
  • Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys(Sato T), Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi MEuropean journal of nutrition48: 6-112009年02月
  • Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-defient mice(You K), Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimokata H, Itoh K, Takahashi S, Yamamoto MGenes to cells : devoted to molecular & cellular mechanisms13: 1159-11702008年11月
  • Possible involvement of advanced glycation end products (AGEs) in the pathogenesis of Alzheimer’s diseaseTakeuchi M, Yamagishi SCurrent pharmaceutical design14: 973-9782008年10月
  • Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation(Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, koga H, Ueno T, Sata MHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.40: 620-6252008年09月
  • Glyceraldehyde-derived advanced glycation end products (AGEs): A novel biomarker of postprandial hyperglycemia in diabetic rats(Kitahara Y), Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi SClinical and experimental medicine8: 175-1772008年09月
  • Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferators-activated receptor-gamma activation(Yamagishi S), Matsui T, Nakamura K, Takeuchi M, Inoue HProtein and peptide letters15: 850-8532008年08月
  • Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes(Nakamura K), Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi TMicrovascular research76: 52-562008年05月
  • Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells(Iwamoto K), Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, Chayama KJournal of gastroenterology.43: 298-3042008年04月
  • Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation(Yoshida T), Yamagishi S, Matsui T, Nakamura K, Ueno T, Takeuchi M, Sata MThe Journal of international medical research.36: 237-2432008年03月
  • Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.(Nakamura K), Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi TDiabetes/metabolism research and reviews24: 109-1142008年02月
  • Telmisartan blocks advanced glycation end product (AGE)-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of peroxisome proliferator-activated receptor-γ (PPAR-γ)(Matsui T), Nakamura K, Takeuchi M, Yamagishi SLetters in drug design & discovery5: 477-4802008年01月
  • Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species(Yamagishi S), Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi TOphthalmic research.40: 10-152008年01月
  • Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression(Yamagishi S), Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi TMicrovascular research75: 130-1342008年01月
  • Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects(Nakamura K), Yamagishi S, Matsui T, Adachi H, Takeuchi M, Imaizumi TClinical and experimental medicine7: 188-1902007年12月
  • Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population(Yamagishi S), Adachi H, Takeuchi M, Enomoto M, Fukami K, Matsui T, Nakamura K, Imaizumi THormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.39: 845-8482007年11月
  • Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxidase synthase (eNOS) reduction through its anti-oxidative properties(Yamagishi S), Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda SProtein and peptide letters14: 832-8352007年08月
  • Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through down-regulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation(Matsui T), Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue HThe Journal of international medical research.35: 482-4892007年07月
  • In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes(Higashimoto Y), Yamagishi S, Nakamura K, Matsui T, Takeuchi M, Noguchi M, Inoue HMicrovascular research74: 65-692007年07月
  • Elevated levels of serum advanced glycation end-products in patients with nonalcoholic steatohepatitis(Hyogo H), Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nakano M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma SJournal of gastroenterology and hepatology.22: 1112-11192007年07月
  • Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells(Yamamoto Y), Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto HDiabetes research and clinical practice.77 Suppl 1: S30-S402007年06月
  • Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s diseaseTakeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S, Yamagishi SMedical hypotheses69: 1358-13662007年06月
  • Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro.(Yokosuka K), Park JS, Jimbo K, Yoshida T, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata KSpine32: E337-E3392007年05月
  • Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes(Unoki H), Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito YDiabetes research and clinical practice.76: 236-2442007年05月
  • Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation(Yokoi M), Yamagishi S, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, Amano-Okamoto T, Ohno SThe British journal of ophthalmology.91: 397-3982007年03月
  • Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro.(Yamagishi S), Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi THormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.39: 233-2352007年03月
  • Oral administration of AST-120 (Kremezine) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders(Yamagishi S), Nakamura K, Matsui T, Inoue H, Takeuchi MMedical hypotheses69: 666-6682007年03月
  • Pigment epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats(Yamagishi S), Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, Yoshida Y, Imaizumi TOphthalmic research.39: 92-972007年02月
  • Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells(Matsui T), Yamagishi S, Nakamura K, Inoue H, Takeuchi MThe Journal of international medical research.35: 107-1122007年02月
  • Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation(Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimuzu T, Sata MVascular disease prevention4: 213-2162007年02月
  • Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes(Jinnouchi Y), Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi TClinical and experimental medicine6: 191-1932006年12月
  • Advanced glycation end-products downregulate intervertebral disc cell production of proteoglycans in vitro(Yokosuka K), Park JS, Jimbo K, Yamada K, Sato K, Tsuru M, Takeuchi M, Yamagishi S, Nagata KJournal of neurosurgery. Spine5: 324-3292006年10月
  • Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species(Niiya Y), Abumiya T, Shichinohe H, Kuroda S, Kikuchi S, Ieko M, Yamagishi S, Takeuchi M, Sato T, Iwasaki YBrain research.1108: 179-1872006年09月
  • RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low molecular weight heparin(Myint KM), Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto HDiabetes.55: 2510-25222006年09月
  • Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects(Yamagishi S), Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi TMetabolism: clinical and experimental55: 1227-12312006年09月
  • Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation.(Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata MDiabetologia49: 3094-30992006年09月
  • Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation.(Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Ueda T, Sata MFEBS letters580: 2788-27962006年09月
  • Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes(Shoji T), Koyama H, Morikawa T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa YDiabetes.55: 2245-22552006年08月
  • Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure(Ueda S), Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda SMolecular medicine (Cambridge, Mass.)12: 180-1842006年08月
  • Toxic advanced glycation end product (TAGE) theory in Alzheimer’s disease(Sato T), Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi MAmerican journal of Alzheimer's disease and other dementias21: 197-2082006年07月
  • Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans(Enomoto M), Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, Imaizumi TMetabolism: clinical and experimental55: 912-9172006年07月
  • Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis(Yamagishi S), Matsui T, Nakamura K, Takeuchi M, Imaizumi TMicrovascular research72: 86-902006年07月
  • TAGE (toxic AGEs) theory in diabetic complications(Sato T), Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi MCurrent molecular medicine6: 351-3582006年05月
  • Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.(Yamagishi S), Nakamura K, Matsui T, Sato T, Takeuchi MMedical hypotheses66:1019-10212006年05月
  • Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression(Yamagishi S), Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi TThe Journal of biological chemistry.281: 20213-202202006年05月
  • Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2(Yamagishi S), Kikuchi S, Nakamura K, Matsui T, Takeuchi M, Inoue HMedicinal chemistry (Sh?riqah (United Arab Emirates))2: 265-2692006年05月
  • Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.(Yamagishi S), Nakamura K, Matsui K, Sato T, Takeuchi MMedical hypotheses66:844-8462006年04月
  • Protective role of pravastatin in the pathogenesis of the metabolic syndrome.(Yamagishi S), Matsui T, Sato T, Takeuchi MMedical hypotheses66:609-6112006年03月
  • Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.(Yamagishi S), Nakamura K, Matsui T, Takeuchi MMedical hypotheses66:273-2752006年02月
  • Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhension molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation(Yamagishi S), Matsui T, Nakamura T, Takeuchi MInternational journal of tissue reactions27: 189-1952005年12月
  • Cytotoxicity of acetaldehyde-derived advanced glycation end-products (AA-AGE) in alcoholic-induced neuronal degenerationTakeuchi M, Saito TAlcoholism, clinical and experimental research.29 (12 Suppl): 220S-224S2005年12月
  • Decerase in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease(Kitamura M), Kitaichi N, Takeuchi M, Kitamei H, Namba K, Yamagishi S, Iwabuchi K, Onoe K, Ohno SThe British journal of ophthalmology.89: 1407-14092005年11月
  • Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells(Yamagishi S), kikuchi S, Takenaka K, Takeuchi MDrugs under experimental and clinical research31: 221-2262005年11月
  • Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats(Yamagishi S), Takeuchi M, Inoue HInternational journal of tissue reactions27: 137-1432005年09月
  • Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression(Yamagishi S), Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue HFEBS letters579: 4265-42702005年08月
  • Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (AGE)-injected rats(Yamagishi S), Takeuchi M, Inoue HDrugs under experimental and clinical research31: 45-512005年06月
  • Met72Thr polymorphism of pigment epithelium-derived factor (PEDF) gene and susceptibility to age-related macular degeneration.(Yamagishi S), Nakamura K, Inoue H, Takeuchi MMedical hypotheses64:1202-12042005年06月
  • Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy(Yokoi M), Yamagishi S, Takeuchi M, Ohgami K, Okamoto T, Saito W, Muramatsu M, Imaizumi T, Ohno SThe British journal of ophthalmology.89: 673-6752005年06月
  • Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders(Yamagishi S), Nakamura K, Takeuchi MMedical hypotheses65: 392-3942005年04月
  • Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease(Yamagishi S), Nakamura K, Inoue H, Kikuchi S, Takeuchi MMedical hypotheses64: 1205-12072005年03月
  • Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients(Yamagishi S), Nakamura K, Inoue H, Kikuchi S, Takeuchi MMedical hypotheses64: 1208-12102005年03月
  • Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells(Yamagishi S), Takeuchi MDrugs under experimental and clinical research31: 13-172005年02月
  • Atheroprotective properties of nifedipine.(Yamagishi S), Takeuchi MInternational journal of tissue reactions27:63-672005年02月
  • Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property(Yamagishi S), Takeuchi MMedical hypotheses64: 476-4782005年01月
  • Pigment epithelium-derived factor (PEDF) inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes(Amano S), Yamagishi S, Inagaki Y, Nakamura K, Takeuchi M, Inoue H, Imaizumi TMicrovascular research69: 45-552005年01月
  • Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrom(Yamagishi S), Nakamura K, Takeuchi MMedical hypotheses65: 152-1542005年01月
  • Receptor for advanced glycation end products is a promising target of diabetic nephropathy(Yamamoto Y), Doi T, Kato I, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Myint KM, Harashima A, Takeuchi M, Takasawa S, Okamoto H, Hashimoto N, Asano M, Yamamoto HAnnals of the New York Academy of Sciences.1043: 562-5662005年
  • Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling(Yamagishi S), Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi TThe American journal of pathology.165: 1865-18742004年12月
  • AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction(Fukami K), Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda SKidney international.66: 2137-21472004年12月
  • Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease(Choei H), Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, kikuchi S, Saito TActa neuropathologica.108: 189-1932004年09月
  • Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells(Sekido H), Suzuki T, Jomori T, Takeuchi M, Yabe-Nishimura C, Yagihashi SBiochemical and biophysical research communications320: 241-2482004年07月
  • Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy(Ohashi S), Abe H, Takahashi T, Yamamoto Y, Takeuchi M, Arai H, Nagata K, Kita T, Okamoto H, Yamamoto H, Doi TThe Journal of biological chemistry.279: 19816-198232004年05月
  • Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in viv(Abe R), Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M, Imaizumi T, Shimizu HThe American journal of pathology.164: 1225-12322004年04月
  • Nifedipine inhibits tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression(Yamagishi S), Takeuchi MDrugs under experimental and clinical research30: 163-1682004年04月
  • Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation(Yamagishi S), Takeuchi MDrugs under experimental and clinical research30: 169-1752004年04月
  • TAGE (toxic AGEs) hypothesis in various chronic diseasesTakeuchi M, Yamagishi SMedical hypotheses63: 449-4522004年03月
  • Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivoTakeuchi M, Yamagishi SMedical hypotheses63: 453-4552004年03月
  • Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions(Abe R), Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu HThe Journal of investigative dermatology122: 461-4672004年02月
  • Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention(Yamagishi S), Nakamura K, Takeuchi M, Imaizumi TInternational journal of clinical pharmacology research24: 129-1342004年02月
  • Involvement of advanced glycation end-products (AGEs) in Alzheimer’s diseaseTakeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi SCurrent Alzheimer research1: 39-462004年02月
  • Advanced glycation end product (AGE) inhibitors and their therapeutic implications in diseaseTakeuchi M, Yamagishi S, Iwaki M, Inagaki Y, Nakamura K, Imaizumi TInternational journal of clinical pharmacology research24: 95-1012004年02月
  • Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer’s disease?(Yamagishi S), Inagaki Y, Takeuchi M, Sasaki NMedical hypotheses63:115-1172004年01月
  • Inhibition of protein kinase C might be harmful to diabetic retinopathy.(Yamagishi S), Takeuchi MMedical hypotheses63:135-1372004年01月
  • AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes(Miura J), Ychigata Y, Yamamoto Y, Takeuchi M, Sakurai S, Watanabe T, Yonekura H, Yamagishi S, Makita Z, Sato A, Omori Y, Yamamoto H, Iwamoto YJournal of diabetes and its complications.18: 53-592004年01月
  • Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neuronsTakeuchi M, Watai T, Sasaki N, Choei H, Iwaki M, Ashizawa T, Inagaki Y, Yamagishi S, kikuchi S, Riederer P, Saitop T, Bucala R, Kameda YJournal of neuropathology and experimental neurology.62: 486-4962003年05月
  • Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy(Yamagishi S), Takeuchi M, Inagaki Y, Nakamura K, Imaizumi TInternational journal of clinical pharmacology research23: 129-1342003年04月
  • Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha(Yamagishi S), Inagaki Y, Abe R, Kikuchi S, Sasaki N, Takeuchi MDrugs under experimental and clinical research29: 141-1452003年04月
  • Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties(Yamagishi S), Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue HMicrovascular research65: 186-1902003年03月
  • Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury(Yonekura H), Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto HThe Biochemical journal.370: 1097-11092003年03月
  • Glycation--a sweet tempter for neuronal death(Kikuchi S), Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N, Tashiro KBrain research reviews41: 306-3232003年03月
  • Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation(Inagaki Y), Yamagishi S, Okamoto T, Takeuchi M, Amano SDiabetologia46: 284-2872003年02月
  • Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons(Kikuchi S), Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, Tashiro KBrain research.964: 228-2362003年02月
  • Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation(Yamagishi S), Amano S, Inagaki Y, Okamoto T, Inoue H, Takeuchi M, Choei H, Sasaki N, Kikuchi SDrugs under experimental and clinical research29: 75-802003年02月
  • Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells(Yamagishi S), Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi MKidney international.63: 464-4732003年02月
  • Serum leveles of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes(Miura J), Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto YJournal of diabetes and its complications.17: 16-212003年01月
  • Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin(Okamoto T), Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita ZThe FASEB journal : official publication of the Federation of American Societies for Experimental Biology16: 1928-19302002年12月
  • Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes(Amano S), Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, Taniko K, Hirooka H, Jomori T, Takeuchi MBiochemical and biophysical research communications299: 183-1882002年11月
  • CS-866, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats(Koga K), Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka MMolecular medicine (Cambridge, Mass.)8: 591-5992002年11月
  • Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes(Petrova R), Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto HJournal of molecular and cellular cardiology.34: 1425-14312002年10月
  • Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro(Okamoto T), Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, Ohna S, Yoshimura ABiochemical and biophysical research communications297: 419-4242002年09月
  • Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes(Yamagishi S), Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita ZMolecular medicine (Cambridge, Mass.)8: 546-5502002年09月
  • Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties(Yamagishi S), Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita ZBiochemical and biophysical research communications296: 877-8822002年08月
  • Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice.(Miyoshi H), Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z, Koike THormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.34: 371-3772002年07月
  • Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats(Yamagishi S), Koga K, Inagaki Y, Amano S, Okamoto T, Takeuchi MDrugs under experimental and clinical research28: 221-2272002年06月
  • Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord(Kikuchi S), Shinpo K, Ogata A, Tsuji S, Takeuchi M, Makita Z, Tashiro KAmyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases3: 63-682002年06月
  • Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques(Sasaki N), Takeuchi M, Choei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita ZNeuroscience letters.326: 117-1202002年06月
  • Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells(Yamagishi S), Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita ZThe Journal of biological chemistry.277: 20309-203152002年06月
  • Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes(Yamagishi S), Inagaki Y, Amano S, Okamoto T, Takeuchi MInternational journal of tissue reactions24: 137-1422002年04月
  • Palmitate-induced apoptosis of microvascular endothelial cells and pericytes(Yamagishi S), Okamoto T, Amano S, Inagaki Y, Koga K, Choei H, Sasaki N, Kikuchi S, Takeuchi M, Makita ZMolecular medicine (Cambridge, Mass.)8: 179-1842002年04月
  • Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons(Kikuchi S), Shinpo K, Takeuchi M, Tsuji S, Yabe I, Niino M, Tashiro KJournal of neuroscience research.69: 373-3812002年03月
  • Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction(Koga K), Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M, Makita ZInternational journal of clinical pharmacology research22: 13-172002年01月
  • Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes(Yamagishi S), Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita ZBiochemical and biophysical research communications290: 973-9782002年01月
  • Immunological detection of a novel advanced glycation end-productTakeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita ZMolecular medicine (Cambridge, Mass.)7: 783-7912001年11月
  • Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice(Yamamoto Y), Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto HThe Journal of clinical investigation108: 261-2682001年07月
  • Effect of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy(Wada R), Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi SEuropean journal of clinical investigation31: 513-5202001年06月
  • Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivoTakeuchi M, Makita ZCurrent molecular medicine1: 305-3152001年06月
  • Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy(Endo M), Yanagisawa K, Tsuchida K, Okamoto T, Matsushita T, higuchi M, Matsuda A, Takeuchi M, Makita Z, Koike THormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.33: 317-3222001年05月
  • Can we identify genes for susceptibility to diabetic microangiopathies using stroke-prone spontaneously hypertensive rat models?(Yamagishi S), Takeuchi M, Unoki HMedical hypotheses56:510-5122001年04月
  • Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease(Sasaki N), Toki S, Choei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita ZBrain research.888: 256-2622001年01月
  • Advanced glycation end products and the pathogenesis of diabetic nephropathy.(Yamagishi S), Takeuchi M, Makita ZContributions to nephrology134:30-352001年
  • Neurotoxicity of advanced glycation end-products for cultured cortical neuronsTakeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamagzaki M, Koike T, Kameda Y, Makita ZJournal of neuropathology and experimental neurology.59: 1094-11052000年12月
  • Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivoTakeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda YMolecular medicine (Cambridge, Mass.)6: 114-1252000年02月
  • Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patientsTakeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike TMolecular medicine (Cambridge, Mass.)5: 393-4051999年06月
  • Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients.(K.Yanagisawa), Z.Makita, K.Shiroshita, T.Ueda, S.Kuwajima, M.Takeuchi, T.KoikeMetabolism: clinical and experimental47:1348-13531998年11月
  • Preparation and biological activity of manno- and galacto-validamines, new 5a-carba-glycosylamines as α-glycosidase inhibitors.(Kameda Y), Kawashima K, Takeuchi M, Ikeda K, Asano N, Matsui KCarbohydrate research300:259-2641997年
  • Interactions of Escherichia coli endonuclease IV and exonuclease III with abasic sites in DNA.Takeuchi M, Lillis R, Demple B, Takeshita MThe Journal of biological chemistry.269:21907-219141994年
  • Trehalase inhibitors, validoxylamine A and related compounds as insecticides.(Asano N), Takeuchi M, Kameda Y, Matsui K, Kono YThe Journal of antibiotics43:722-7261990年
  • Purification and some properties of cytochrome c550 from Flavobacterium saccharophilum.Takeuchi M, Matsui KBiological & pharmaceutical bulletin38:1098-10991990年
  • Inhibitory effect of validamine, valienamine, and valiolamine on activities of carbohydrases in rat small intestinal brush border membranes.Takeuchi M, Takai N, Asano N, Kameda K, Matsui KBiological & pharmaceutical bulletin38:1970-19721990年
  • Inhibitory effect of pseudo-aminosugars on oligosaccharide glucosidases I and II and on lysosomal α-glucosidase from rat liver.Takeuchi M, Kamata K, Yoshida M, Kameda Y, Matsui KJournal of biochemistry.108:42-461990年
  • Chemical modification by 2,4,6-trinitrobenzene-sulfonic acid (TNBS) of an essential amino groups in 3-ketovalidoxylamine A C-N lyase.Takeuchi M, Neyazaki K, Matsui KBiological & pharmaceutical bulletin38:1419-14201990年
  • Preparation of 3-amino-3-deoxy derivatives of trehalose and sucrose and their activities.(Asano N), Katayama K, Takeuchi M, Furumoto T, Kameda K, Matsui KThe Journal of antibiotics42:585-5901989年
  • Purification and properties of soluble D-glucoside 3-dehydrogenase from Flavobacterium saccharophilum.Takeuchi M, Asano N, Kameda Y, Matsui KBioscience, biotechnology, and biochemistry52:1905-19121988年
  • Physiological role of glucoside 3-dehydrogenase and cytochrome c551 in the sugar oxidizing system of Flavobacterium saccharophilum.Takeuchi M, Asano N, Kameda Y, Matsui KJournal of biochemistry.103:938-9431988年
  • Fluorometric studies on the role of calcium in substrate binding to 3-ketovalidoxylamine A C-N lyase.Takeuchi M, Asano N, Kameda Y, Matsui KBiological & pharmaceutical bulletin36:3540-35451988年
  • Purification and properties of glucoside 3-dehydrogenase from Flavobacterium Saccharophilum.Takeuchi M, Ninomiya K, Kawabata K, Asano N, Kameda Y, Matsui KJournal of biochemistry.100:1049-10551986年
  • Chemical modification by diethylpyrocarbonate of an essential histidine residues in 3-ketovalidoxylamine A C-N lyase.Takeuchi M, Asano N, Kameda Y, Matsui KJournal of biochemistry.99:1571-15771986年
  • Purification and properties of 3-ketovalidoxylamine A C-N lyase from Flavobacterium saccharophilum.Takeuchi M, Asano N, Kameda Y, Matsui KJournal of biochemistry.98:1631-16381985年
  • Epivaliolamine and deoxyvalidamine, new pseudo-aminosugars produced by Streptomyces hygroscopicus.(Kameda Y), Asano N, Takeuchi M, Yamaguchi T, Matsui K, Horii S, Fukase HThe Journal of antibiotics38:1816-18181985年
  • Valiolamine, a new α-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus.(Kameda Y), asano N, Yoshikawa M, Takeuchi M, Yamaguchi T, Matsui K, Horii S, Fukase HThe Journal of antibiotics37:1301-13071984年
  • Studies on cation-induced membrane vesicle aggregation of porcine intestinal brush borders.(Ohyashiki T), Takeuchi M, Mohri TJournal of biochemistry.95:881-8861984年
  • Microbial degradation of validamicin A by Flavobacterium saccharophilum-Enzymatic cleavage of C-N linkage in validoxylamine A-.(Asano N), Takeuchi M, Ninomiya K, Kameda Y, Matsui KThe Journal of antibiotics37:859-8671984年
  • A conformation change of the porcine intestinal calcium binding protein on binding of Ca2+.(Chiba K), Takeuchi M, Mohri T, Ohayshiki TBiological & pharmaceutical bulletin31:966-9701983年
  • Temperature-induced transitions of porcine intestinal brush border membranes.(Ohyashiki T), Takeuchi M, Kodera M, Mohri TBiochimica et biophysica acta-molecular and cell biology of lipids688:16-221982年

書籍等出版物

  • Toxic AGEsとはなんですか.ToxicでないAGEsがあるということですか.
    老化物質AGEsワールドに迫る! アンチエイジングのための100の質問
    竹内正義
    メディカルレビュー社 2014年06月
  • AGEsと筋委縮性側索硬化症,パーキンソン病,クロイツフェルトヤコブ病との間には,何か関連性が指摘されていますか.
    老化物質AGEsワールドに迫る! アンチエイジングのための100の質問
    高田尊信, 竹内正義
    メディカルレビュー社 2014年06月
  • AGEsとアルツハイマー病との関連性について教えて下さい
    老化物質AGEsワールドに迫る! アンチエイジングのための100の質問
    逆井(坂井)亜紀子, 竹内正義
    メディカルレビュー社 2014年06月
  • AGEsとアルツハイマー病・神経変性疾患
    AGEsと老化 -糖化制御からみたウエルエイジング-(太田博明、山岸昌一)
    竹内正義
    メディカルレビュー社 2013年01月
  • 生活習慣病の発症・進展におけるToxic AGEs (TAGE)-RAGE系の関与:-新たな治療戦略-
    金沢医科大学雑誌
    竹内正義
    金沢医科大学出版局 2012年12月
  • Toxic advanced glycation end-products: TAGEの多様な疾患への関与
    日本薬理学雑誌
    竹内正義
    日本薬理学会 2012年05月
  • AGEsと肝疾患
    Anti-aging Medicine
    竹内正義
    メディカルレビュー社 2012年02月
  • 生活習慣病におけるToxic AGEs (TAGE)-RAGE系の関与とその阻止
    日本未病システム学会雑誌
    竹内正義
    日本未病システム学会 2011年07月
  • NASHの発症・進展におけるtoxic AGEs (TAGE)-RAGE系の関与
    アルコールと医学生物学
    竹内正義, 瀧野純一, 兵庫秀幸, 山岸昌一
    東洋書店 2011年04月
  • 食事性AGEsと未病-生活習慣病におけるTAGE病因説と食事性AGEsのクロストーク-
    日本未病システム学会雑誌
    (河上美穂子), 白井ひかり, 瀧野純一, 佐藤 隆, 山岸昌一, 竹内正義
    日本未病システム学会 2010年
  • 血管障害のバイオマーカーとしてのAGEs,可溶型RAGEの意義
    血管医学
    竹内正義, 瀧野純一, 山岸昌一
    メディカルレビュー社 2010年02月
  • 生活習慣病におけるTAGE病因説と食事性AGEsのクロストーク
    Vitamembrane
    竹内正義
    Vitamembrane研究会 2010年03月
  • ビタメンブレンと酸化ストレス
    透析会誌
    (中村 司), 佐藤英一, 藤原信治, 川越康博, 上田喜彦, 小出 輝, 竹内正義, 山岸昌一, 長田しをり, 大和田滋, 外山勝英, 野出孝一
    日本透析医学会 2010年
  • 終末糖化産物と肝疾患―とくに非アルコール性脂肪性肝炎に与える影響に関連して
    G. I. Research
    (石飛朋和), 兵庫秀幸, 木村友希, 鍋島由宝, 菅野啓司, 山岸昌一, 竹内正義, 田妻進, 茶山一彰
    先端医学社 2009年
  • 食事性AGEsと未病
    未病と抗老化
    竹内正義, 古野理美, 小林由佳, 河上美穂子, 山岸昌一
    (財)博慈会 2008年04月
  • 血栓形成とAGEs
    生体の科学
    (山岸昌一), 竹内正義
    医学書院 2007年12月
  • 終末糖化産物(AGEs)による肝線維化促進作用-酸化ストレスの関与とそのメカニズム-
    G. I. Research
    (岩本慶子), 兵庫秀幸, 井上基樹, 鍋島由宝, 菅野啓司, 山岸昌一, 竹内正義, 田妻 進, 茶山一彰
    先端医学社 2007年
  • 糖尿病血管合併症における終末糖化産物(AGEs)の関与とその阻止-AGEsを標的としたクレメジンの新規血管障害保護作用-
    血管医学
    (山岸昌一), 竹内正義
    メディカルレビュー社 2007年02月
  • 生活習慣病における終末糖化産物(AGEs)の関与とその阻止
    YAKUGAKU ZASSHI
    竹内正義, 佐藤隆, 山岸昌一
    日本薬学会 2007年
  • AGEs(終末糖化産物)にはどんなものがあるか -毒性終末糖化産物仮説
    生体の科学
    竹内正義, 佐藤 隆, 瀧野純一, 小林由佳, 古野理美, 山岸昌一
    医学書院 2007年12月
  • AGEsの概要と臨床応用
    日本医事新報
    竹内正義
    日本医事新報社 2007年
  • 終末糖化産物AGEs
    内分泌・糖尿病科
    (佐藤 隆), 下垣内徳子, 竹内正義
    科学評論社 2006年01月
  • Role of advanced glycation end products (AGEs) in cell growth and death
    Focus on Cell Apoptosis Research, Daniel W. Cho eds.,
    (Yamagishi S), Nakamura K, Matsui T, Inoue H, Makino T, Shimizu T, Takeuchi M
    Nova Science 2006年
  • 酸化ストレスマーカーと疾患・病態(話題:カルボキシメチルリジン)
    臨床検査
    竹内正義
    医学書院 2005年02月
  • 蛋白質の消化、吸収、代謝
    栄養士・介護福祉士のための解剖生理学
    竹内正義
    メディカルレビュー社 2005年05月
  • 臨床編:第4章 薬剤・治療、19.AGEs阻害薬
    酸化ストレスナビゲーター
    (山岸昌一), 竹内正義, 今泉 勉
    メディカルレビュー社 2005年
  • 臨床編:第2章 検査法、6.カルボキシメチルリジン
    酸化ストレスナビゲーター
    竹内正義, 山岸昌一
    メディカルレビュー社 2005年
  • 糖質の消化、吸収、代謝
    栄養士・介護福祉士のための解剖生理学
    竹内正義
    メディカルレビュー社 2005年05月
  • 神経変性疾患とグリケーション―筋萎縮性側索硬化症とパーキンソン病―
    脳循環代謝
    (菊地誠二), 田代 淳, 新保和賢, 竹内正義
    脳循環代謝学会 2005年
  • 基礎編:第1章 化学・生化学・薬理学、9.AGEs
    酸化ストレスナビゲーター
    竹内正義, 岩城実奈, 山岸昌一
    メディカルレビュー社 2005年
  • Toxic AGEs -RAGE結合活性からみた考察
    血管医学
    竹内正義, 佐藤 隆, 下垣内徳子
    メディカルレビュー社 2005年01月
  • 生活習慣病におけるTAGE (toxic AGEs) 病因説
    北陸大学紀要
    竹内正義
    北陸大学 2004年03月
  • アルコール性脳神経障害におけるアセトアルデヒド由来AGEs (AA-AGE) の臨床的意義
    アルコールと医学生物学
    竹内正義, 齋藤利和
    東洋書店 2004年
  • Pericytes and angiogenesis
    Progress in angiogenesis research
    (Yamagishi S), Inagaki Y, Nakamura K, Takeuchi M, Imaizumi T
    Nova Science 2004年
  • CAPD液中GDPs等に由来するAGEsの生成経路の総括と生物作用
    腎と透析 別冊「腹膜透析2004」
    竹内正義, 岩城実奈, 亀田幸彦, 山岸昌一, 平井麻美, 山本敬史, 狩野智一, 名本真二
    東京医学社 2004年
  • AGEsの基礎:2.生体内AGEsの生成過程
    AGEs研究の最前線
    竹内正義, 岩城実奈
    メディカルレビュー社 2004年05月
  • 高血糖とAGE:新しい治療戦略
    BIO Clinica
    竹内正義, 山岸昌一, 山本 博
    北隆館 2003年06月
  • ラットにおけるアセトアルデヒド由来AGEの血清および肝小葉内分布
    アルコールと医学生物学
    (永井佳世子), 堤 幹宏, 福村 敦, 土島 睦, 高瀬修二郎, 山岸昌一, 竹内正義
    東洋書店 2003年
  • 糖尿病と酸化ストレス-高血糖による細胞内酸化ストレス増強機序:終末糖化産物-
    Diabetes Frontier
    (渡辺琢夫), 山本靖彦, 櫻井繁, 竹内正義, 米倉秀人, 山本 博
    メディカルレビュー社 2002年
  • 新時代の糖尿病学(3)-病因・診断・治療研究の進歩-
    日本臨床(増刊)
    竹内正義, 山岸昌一, 牧田善二
    日本臨床社 2002年04月
  • 糖尿病腎症の発症機構とその治療
    内科
    (山岸昌一), 竹内正義, 牧田善二
    南江堂 2001年

受賞

  • 2015年10月 第22回日本未病システム学会学術総会優秀演題賞 飲食物中AGEs及び糖毒性の真実〜現代の食生活に潜む落とし穴〜
    竹内正義
  • 2014年11月 第21回日本未病システム学会学術総会優秀賞 不妊治療バイオマーカーとしてのToxic AGEs (TAGE) の有用性
    竹内正義
  • 2013年11月 日本未病システム学会学術総会 第20回日本未病システム学会学術総会優秀演題賞 未病マーカーとしてのtoxic AGEs (TAGE) の有用性
    竹内正義,
  • 2013年02月 大阪商工会議所・大阪医薬品協会 平成24年度バイオビジネスアワードJAPAN彩都賞 非アルコール性脂肪肝炎(Nonalcoholic steatohepatitis, NASH)の発症・進展における新規ターゲットとしてのtoxic AGEs (TAGE)
    竹内正義,
  • 2011年05月 第11回日本抗加齢医学会 優秀演題賞 非アルコール性脂肪性肝炎 (NASH) の発症・進展におけるtoxic AGEs (TAGE)-RAGE系の関与
    竹内正義,
  • 2010年11月 第30回日本アルコール医学生物学研究会学術集会 優秀演題賞 NASHの発症・進展におけるtoxic AGEs (TAGE)-RAGE系の関与
    竹内正義,
  • 2010年11月 第17回日本未病システム学会 研究奨励賞 生活習慣病におけるToxic AGEs (TAGE)-RAGE系と食後高血糖及び食事性AGEsのクロストーク
    竹内正義,
  • 2010年06月 第10回日本抗加齢医学会 優秀演題賞 Toxic AGEs (TAGE)-RAGE病因説とアンチエイジング
    竹内正義,
  • 2009年05月 第52回日本糖尿病学会 優秀演題賞 Toxic AGEs(TAGE)の細胞障害性は食後高血糖と食事性AGEsによってコントロールされる
    竹内正義,
  • 2004年03月 高岡市 高岡市民文化賞 生活習慣病や認知症、がんなど慢性疾患の発症、進展について、生体内の共通病因物質が関与するとする「TAGE病因説」を提唱、解明することにより、慢性疾患の発症、進展予防の可能性を広げた。
    竹内正義,
  • 2004年03月 第24回日本アルコール医学生物学研究会学術集会 優秀演題賞 アルコール性脳神経障害におけるアセトアルデヒド由来AGEs(AA-AGE)の臨床的意義
    竹内正義,
  • 1990年07月 日本薬学会北陸支部 奨励賞 バリダマイシンAのC-N結合開裂酵素に関する研究
    竹内正義,

競争的資金

  • 生活習慣病の発症・進展における新規ターゲットとしてのToxic AGEs(TAGE)の関与とその阻止
    文部科学省:文部科学省地域イノベーション戦略支援プログラム(国際競争力強化地域)
    研究期間:2016年 - 2017年  
    代表者:竹内正義
  • 現代の飲食物が関与する細胞内毒性終末糖化産物の生成/蓄積と各種細胞障害機序の解明
    文部科学省:科学研究費 基盤研究(A)
    研究期間:2016年 - 2020年  
    代表者:竹内正義
  • 悪性腫瘍の発症・進展における毒性終末糖化産物の関与
    その他:(公財)北國がん研究振興財団北國がん基金研究助成金
    研究期間:2015年 - 2015年  
    代表者:竹内正義
  • 現代の食習慣の特徴と非アルコール性脂肪性肝障害の発症・進展との関連性に関する研究
    文部科学省:科学研究費 基盤研究(B)
    研究期間:2013年 - 2015年  
    代表者:竹内正義
  • 生活習慣病の発症・進展における新規ターゲットとしてのToxic AGEs(TAGE)の関与とその阻止
    その他省庁:文部科学省地域イノベーション戦略支援プログラム
    研究期間:2013年 - 2016年  
    代表者:竹内正義
  • 生活習慣病予防における食後高血糖および食事性AGEsの関与に関する研究
    文部科学省:科学研究費 基盤研究(B)
    研究期間:2010年 - 2012年  
    代表者:竹内正義


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.